Under 10% of patients that would benefit from weight-loss injections such as Wegovy have access to them, caution the World Health Organization as it publishes its initial guidance on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is calling for broader and more equitable access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidelines acknowledges that obesity is a lifelong illness that can be addressed with comprehensive and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to broad access to the treatments that can assist patients in reducing substantial body mass, notes the body.
Skinny Jab Scarcity
Even in the present most optimistic scenario, the production of such drugs would only suffice for around 100 million people – less than 10% of eligible patients, per the health organization.
The advice encourages nations and manufacturers to increase access, by strategies including licensing agreements.
Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.
The Way Obesity Jabs Function
The injections imitate a body's own hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so individuals reduce food intake.
Individuals usually begin shedding pounds within a few weeks of commencing the regular doses.
Evidence suggests people may put most of the weight back on within a year of stopping the drug, as their usual appetite resume.
To be carrying excess weight raises your risk for contracting health problems, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.
Excess weight affects individuals in all nations and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
